Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer.
Simonaggio A, Michot JM, Voisin AL, Le Pavec J, Collins M, Lallart A, Cengizalp G, Vozy A, Laparra A, Varga A, Hollebecque A, Champiat S, Marabelle A, Massard C, Lambotte O. Simonaggio A, et al. Among authors: voisin al. JAMA Oncol. 2019 Sep 1;5(9):1310-1317. doi: 10.1001/jamaoncol.2019.1022. JAMA Oncol. 2019. PMID: 31169866 Free PMC article.
Myocarditis with Immune Checkpoint Blockade.
Ederhy S, Voisin A-L, Champiat S. Ederhy S, et al. N Engl J Med. 2017 Jan 19;376(3):290-1. doi: 10.1056/NEJMc1615251. N Engl J Med. 2017. PMID: 28102662 No abstract available.
Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy.
Le Burel S, Champiat S, Routier E, Aspeslagh S, Albiges L, Szwebel TA, Michot JM, Chretien P, Mariette X, Voisin AL, Lambotte O. Le Burel S, et al. Among authors: voisin al. Ann Rheum Dis. 2018 Mar;77(3):468-470. doi: 10.1136/annrheumdis-2016-210820. Epub 2017 Feb 27. Ann Rheum Dis. 2018. PMID: 28242618 No abstract available.
Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis.
Le Burel S, Champiat S, Mateus C, Marabelle A, Michot JM, Robert C, Belkhir R, Soria JC, Laghouati S, Voisin AL, Fain O, Mékinian A, Coutte L, Szwebel TA, Dunogeant L, Lioger B, Luxembourger C, Mariette X, Lambotte O. Le Burel S, et al. Among authors: voisin al. Eur J Cancer. 2017 Sep;82:34-44. doi: 10.1016/j.ejca.2017.05.032. Epub 2017 Jul 10. Eur J Cancer. 2017. PMID: 28646772
Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies.
Collins M, Michot JM, Danlos FX, Mussini C, Soularue E, Mateus C, Loirat D, Buisson A, Rosa I, Lambotte O, Laghouati S, Chaput N, Coutzac C, Voisin AL, Soria JC, Marabelle A, Champiat S, Robert C, Carbonnel F. Collins M, et al. Among authors: voisin al. Ann Oncol. 2017 Nov 1;28(11):2860-2865. doi: 10.1093/annonc/mdx403. Ann Oncol. 2017. PMID: 29045560 Free article.
Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment.
Picchi H, Mateus C, Chouaid C, Besse B, Marabelle A, Michot JM, Champiat S, Voisin AL, Lambotte O. Picchi H, et al. Among authors: voisin al. Clin Microbiol Infect. 2018 Mar;24(3):216-218. doi: 10.1016/j.cmi.2017.12.003. Epub 2017 Dec 18. Clin Microbiol Infect. 2018. PMID: 29269089 Free article. No abstract available.
Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease.
Danlos FX, Voisin AL, Dyevre V, Michot JM, Routier E, Taillade L, Champiat S, Aspeslagh S, Haroche J, Albiges L, Massard C, Girard N, Dalle S, Besse B, Laghouati S, Soria JC, Mateus C, Robert C, Lanoy E, Marabelle A, Lambotte O. Danlos FX, et al. Among authors: voisin al. Eur J Cancer. 2018 Mar;91:21-29. doi: 10.1016/j.ejca.2017.12.008. Epub 2018 Jan 10. Eur J Cancer. 2018. PMID: 29331748
30 results